FDA: Issues Botanical Drug Product RFI to Advance Development

• The U.S. Food and Drug Administration has issued a Request for Information (RFI) to gather public input on advancing the development of botanical drug products.
• This initiative, part of a Trump Administration effort, seeks to streamline regulatory pathways and foster innovation for plant-derived medicines.
• The RFI specifically requests feedback on challenges in botanical research, innovative development approaches, and potential updates to FDA guidance.
• The FDA aims to build on its experience with four approved botanical prescription drugs and other botanical ingredients marketed under OTC monographs.
• Stakeholders must submit comments electronically or via mail by November 3, 2026, referencing Docket No. FDA-2026-N-9550.

This initiative represents a significant opportunity for researchers, clinicians, industry, and other interested parties to directly influence the future regulatory framework and development pathways for botanical drug products.

The U.S. Food and Drug Administration (FDA) has initiated a Request for Information (RFI) to solicit public feedback on strategies to advance the development of botanical drug products. This move aligns with a broader Trump Administration objective to streamline regulatory processes and encourage medical innovation. Botanical drug products are defined as substances that either contain or are derived from plant materials, algae, macroscopic fungi, or combinations thereof, and are intended for the diagnosis, cure, mitigation, treatment, or prevention of disease.

While there is considerable public interest in these natural products, their inherent complexity and variability often pose unique challenges for scientific research, product development, and the subsequent regulatory review process. The FDA botanical drug product RFI aims to address these complexities by gathering diverse perspectives from across the scientific and medical communities.

Acting FDA Commissioner Kyle Diamantas J.D. underscored the agency's commitment to modernizing regulatory frameworks under the Trump Administration, ensuring that promising natural health options undergo rigorous scientific evaluation. He highlighted botanical drug products as a crucial area where enhanced scientific development could unlock new therapeutic opportunities for American patients, all while upholding the highest safety standards. Marta Sokolowska, Ph.D., Deputy Center Director for Substance Use and Behavioral Health within the FDA's Center for Drug Evaluation and Research, further noted that given the widespread use of botanicals for self-treatment, greater scientific advancement in this field could yield significant new patient benefits. She emphasized the FDA's desire to hear directly from researchers, clinicians, industry, and other stakeholders regarding the obstacles they encounter and practical solutions that could facilitate the delivery of safe and effective botanical drugs to patients.

The FDA is building upon its existing experience with botanical products. To date, four botanical products have successfully navigated the agency's new drug application (NDA) and biologics license application (BLA) pathways to receive approval for marketing as prescription drugs. Additionally, certain botanical active ingredients, such as psyllium and witch hazel, are permitted to be marketed under specific over-the-counter (OTC) monographs. The agency aims to leverage insights from these approved products and other FDA botanical drug development programs to accelerate progress through increased scientific and stakeholder engagement.

As part of these ongoing efforts, the FDA recently collaborated with the Reagan-Udall Foundation for the FDA, hosting a roundtable discussion to gather information on both the challenges and opportunities in advancing botanical drug development. The agency also plans to convene a joint workshop with the European Medicines Agency on September 25, 2026, to delve into regulatory considerations for herbal medicinal products regulation and botanical drug products intended for medicinal use.

Through this Request for Information, the FDA is actively seeking comprehensive feedback on a range of critical topics. These include the challenges encountered in botanical research and drug development, innovative approaches that could support and accelerate development, and potential updates to existing FDA guidance and other resources. The agency is also interested in public input on quality standards, appropriate study designs for complex botanical mixtures, and the potential utility of real-world evidence and other scientifically credible information to facilitate development.

The public has a 60-day window following the RFI's publication in the Federal Register to submit their comments. Stakeholders are strongly encouraged to submit their feedback electronically via https://www.regulations.gov. To locate the relevant submission portal for FDA public input botanical drugs, users should search for Docket No. FDA-2026-N-9550, which is titled "Advancing Development of Botanical Drug Products; Request for Information." For those preferring traditional mail, written or paper submissions can be sent to Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. The botanical drug comment deadline for submitting comments is November 3, 2026, and any submissions received after this date will not be considered by the agency.

As an agency within the U.S. Department of Health and Human Services, the FDA is tasked with safeguarding public health by ensuring the safety, effectiveness, and security of human and veterinary drugs, vaccines, other biological products for human use, and medical devices. This RFI underscores the agency's proactive stance in adapting its regulatory frameworks to accommodate the unique characteristics of botanical drug products.

This initiative represents a significant opportunity for researchers, clinicians, industry, and other interested parties to directly influence the future regulatory framework and development pathways for botanical drug products. The insights gathered will be instrumental in shaping future FDA regulatory pathways botanical guidance and policies, potentially impacting how these complex medicines are researched, developed, and brought to market, thereby affecting market access and product innovation for years to come.

Lawyers representing pharmaceutical companies, botanical product manufacturers, or related stakeholders should advise clients on the opportunity to submit comments to the FDA's Request for Information by November 3, 2026, to influence the future regulatory framework and development pathways for botanical drug products. Compliance officers should monitor this RFI's outcome for potential changes in FDA guidance affecting product development and market access.

Source: Original reporting via FDA announcement.